Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease

Dig Dis Sci. 2020 Nov;65(11):3238-3243. doi: 10.1007/s10620-020-06226-1. Epub 2020 Apr 1.

Abstract

Introduction: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide. Nonalcoholic steatohepatitis (NASH), is a more severe type of NAFLD. Exercise improves NASH, by reversing steatosis, and may arrest fibrosis. However, the mechanisms underlying these interactions are unknown. AMP-activated protein kinase (AMPK) is a fuel-sensing enzyme that is activated by energy stress. Mammalian target of rapamycin in complex 1 (mTORC1) is a nutrient sensor that regulates protein synthesis. In NASH, AMPK activity is low and mTORC1 is high. In healthy persons, exercise activates AMPK and suppresses mTORC1. We examined the effects of exercise on hepatic ribosomal protein S6 phosphorylation, a downstream target of AMPK and mTORC1 in patients with NASH.

Methods: Three subjects with biopsy-proven NASH underwent a structured, 20-week aerobic exercise intervention, five-days a week for 30-min at a moderate intensity (40-55% of VO2max). Immunofluorescence staining for rpS6 phosphorylation in hepatic tissue was quantified by ImageJ software.

Results: Following 20-weeks of aerobic exercise, rpS6 levels were significantly attenuated (3.9 ± 1.9 pre-exercise vs. 1.4 +/0.4 post-exercise, p = 0.04).

Conclusions: These findings suggest exercise modulates the AMPK/mTORC1 pathway in patients with NASH and may guide the design of future studies into the mechanism of how exercise improves NASH and possibly reverses fibrosis.

Keywords: Fatty liver; Fitness; Mechanism; Nonalcoholic fatty liver disease; Physical activity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Adolescent
  • Adult
  • Aged
  • Biopsy
  • Body Composition
  • Exercise Therapy / methods*
  • Female
  • Humans
  • Male
  • Mechanistic Target of Rapamycin Complex 1 / metabolism
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Non-alcoholic Fatty Liver Disease / therapy*
  • Phosphorylation
  • Ribosomal Protein S6 / metabolism*

Substances

  • Ribosomal Protein S6
  • Mechanistic Target of Rapamycin Complex 1
  • AMP-Activated Protein Kinases